![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Monday, November 22, 2021 12:58:09 PM
Unique Protocol ID: RLF-100_002
Brief Title: Inhaled ZYESAMI™ (Aviptadil Acetate) for the Treatment of Severe COVID-19 (AVICOVID-2)
Official Title: Inhaled ZYESAMI™ for the Treatment of Severe COVID-19
Secondary IDs:
Open or close this module Study Status
Record Verification: October 2021 November 2021
Overall Status: Recruiting
Study Start: February 15, 2021
Primary Completion: December 15, 2021 [Anticipated]
[color=red]Study Completion: December 31, 2021 [Anticipated][/color]
The study IV (Remdesivir/Placebo) will now be finished already in the 1st Q to read out ( more safety!!!)data.....
FEATURED BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • Jul 2, 2024 7:19 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM